Spotlight on pembrolizumab in the treatment of advanced melanoma

Drug Design, Development and Therapy

Volumn 9, Issue , 2015, Pages 2883-2886

  Rajakulendran, Thanashan ^a   Adam, David N ^b  

^a UNIVERSITY OF TORONTO   (Canada)

^b ST MICHAEL'S HOSPITAL   (Canada)

Author keywords

Immune checkpoint; Melanoma; PD 1; PD L1; Pembrolizumab

Indexed keywords

CYTOTOXIC T LYMPHOCYTE ANTIGEN 4; PEMBROLIZUMAB; PROGRAMMED DEATH 1 RECEPTOR; ANTINEOPLASTIC AGENT; MONOCLONAL ANTIBODY;

ABDOMINAL PAIN; ADRENAL INSUFFICIENCY; ADVANCED CANCER; ANEMIA; CELLULITIS; COUGHING; DECREASED APPETITE; DIARRHEA; DRUG APPROVAL; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; DRUG TREATMENT FAILURE; DRUG WITHDRAWAL; DYSPNEA; FATIGUE; FOOD AND DRUG ADMINISTRATION; HUMAN; HYPERTHYROIDISM; HYPERTRANSAMINASEMIA; HYPOTHYROIDISM; KIDNEY FAILURE; METASTATIC MELANOMA; NAUSEA; NEPHRITIS; OUTCOME ASSESSMENT; PHASE 1 CLINICAL TRIAL (TOPIC); PNEUMONIA; PROCESS DEVELOPMENT; PROTEIN EXPRESSION; PROTEIN TARGETING; PRURITUS; RASH; REVIEW; IMMUNOLOGY; MELANOMA; METASTASIS; MOLECULARLY TARGETED THERAPY; PATHOLOGY; PROGNOSIS; SKIN NEOPLASMS; UNITED STATES;

ANTIBODIES, MONOCLONAL, HUMANIZED; ANTINEOPLASTIC AGENTS; DRUG APPROVAL; HUMANS; MELANOMA; MOLECULAR TARGETED THERAPY; NEOPLASM METASTASIS; PROGNOSIS; SKIN NEOPLASMS; UNITED STATES; UNITED STATES FOOD AND DRUG ADMINISTRATION;

EID: 84933074028     PISSN: None     EISSN: 11778881     Source Type: Journal    
DOI: 10.2147/DDDT.S78036     Document Type: Review

References (15)

1. Aris M, Barrio MM. Combining immunotherapy with oncogene-targeted therapy: a new road for melanoma treatment. Front Immunol. 2015;6:46.
2. Bhatia S, Tykodi SS, Thompson JA. Treatment of metastatic melanoma: an overview. Oncology (Williston Park). 2009;23(6):488-496.
3. Kee D, McArthur G. Targeted therapies for cutaneous melanoma. Hematol Oncol Clin North Am. 2014;28(3):491-505.
4. Robert C, Karaszewska B, Schachter J, et al. Improved overall survival in melanoma with combined dabrafenib and trametinib. N Engl J Med. 2015;372(1):30-39.
5. Menzies AM, Long GV. Systemic treatment for BRAF-mutant melanoma: where do we go next? Lancet Oncol. 2014;15(9):e371-e381.
6. Rajakulendran T, Adam DN. Bench to bedside: mechanistic principles of targeting the RAF kinase in melanoma. Int J Dermatol. 2014; 53(12):1428-1433.
7. Fedorenko IV, Gibney GT, Sondak VK, Smalley KS. Beyond BRAF: where next for melanoma therapy? Br J Cancer. 2015;112(2): 217-226.
8. Vinay DS, Ryan EP, Pawelec G, et al. Immune evasion in cancer: mechanistic basis and therapeutic strategies. Semin Cancer Biol. Epub 2015 Mar 25.
9. Shin DS, Ribas A. The evolution of checkpoint blockade as a cancer therapy: what's here, what's next? Curr Opin Immunol. 2015;33C: 23-35.
10. Callahan MK, Wolchok JD. At the bedside: CTLA-4- and PD-1-blocking antibodies in cancer immunotherapy. J Leukoc Biol. 2013; 94(1):41-53.
11. Robert C, Ribas A, Wolchok JD, et al. Anti-programmed-death-receptor-1 treatment with pembrolizumab in ipilimumab-refractory advanced melanoma: a randomised dose-comparison cohort of a phase 1 trial. Lancet. 2014;384(9948):1109-1117.
12. Tumeh PC, Harview CL, Yearley JH, et al. PD-1 blockade induces responses by inhibiting adaptive immune resistance. Nature. 2014; 515(7528):568-571.
13. Postow MA, Callahan MK, Wolchok JD. Immune checkpoint blockade in cancer therapy. J Clin Oncol. 2015;1-9.
14. Momtaz P, Postow MA. Immunologic checkpoints in cancer therapy: focus on the programmed death-1 (PD-1) receptor pathway. Pharmgenomics Pers Med. 2014;7:357-365.
15. Robert C, Schachter J, Long GV, et al. Pembrolizumab versus ipilimumab in advanced melanoma. N Engl J Med. Epub 2015 Apr 19.